drugset / Trial / NCT00449644

TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

NCT00449644

Phase 2 Completed 208 enrolled Janssen Infectious Diseases BVBA
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to demonstrate that the antibacterial activity of TMC207 is better than placebo when added to a standardized Background Regimen (BR) for treatment of multi-drug resistant TB. Also safety and tolerability will be evaluated.

Timeline

Start
2007-06
Primary completion
2010-03
Completion
2012-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bedaquiline Small molecule 200 mg

Indications